● Recruiting

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Condition: Vaccine-Preventable Diseases · Herpes Zoster · Sponsor: Aribio Lab Co., Ltd.

PhasePhase 1

Planned participants32

Who can joinAll sexes, 50 Years to 64 Years

Healthy volunteersYes

About this study

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.

This description comes directly from the study's public registry record.

Talk to the study team

Gabsoon Noh · +82318817341 · gsnoh75@chamc.co.kr

Always discuss trial participation with your own doctor first.

Locations (2)

The Catholic University of Korea, Eunpyeong St. Mary's Hospital	Seoul, Eunpyeong-gu, South Korea	Recruiting
Bundang CHA General Hospital	Seongnam-si, Gyeonggi-do, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06137755